I. V. Krasilnikova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
I. V. Krasilnikova has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- D. S. Belkina
National Medical Research Center for Hematology, Ministry of Health of Russia
2 shared publications - Ekaterina A. Fastova
National Medical Research Center for Hematology
2 shared publications - Eugene Eugeneevich Zvonkov
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
2 shared publications - N. P. Podrezov
National Medical Research Center of Hematology
2 shared publications - Raisa V. Dorzhieva
National Medical Research Center of Hematology
2 shared publications - Yana Konstantinovna Mangasarova
National Medical Research Center for Hematology
2 shared publications
Latest Publications
- 26 August 2026
- Published by Media Sphere Publishing Group in Russian Bulletin of Obstetrician-Gynecologist
- Vol. 26 (4)
Lymphoproliferative diseases during pregnancy. Long-term outcomes for mother and child
Lymphoproliferative diseases are the third most common type of malignant neoplasms detected in pregnant patients. The high effectiveness of the therapy of such patients makes it relevant to study the long-term results of their treatment, as well as the health status of their children. Objective. To present the features of the course of pregnancy and its outcomes in patients with an identified lymphoproliferative disease during pregnancy, to evaluate the long-term effects of the treatment, as well as to analyze the physical development of children born to mothers with lymphoma, at birth and in the catamnesis. Materials and methods. From 2009 to 2025, 44 patients with a diagnosis of lymphoproliferative disease during pregnancy were treated at the Federal State Budgetary Institution “NMRC of Hematology” of the Ministry of Health of the Russian Federation. 28 (64%) pregnant women were diagnosed with non-Hodgkin’s lymphoma, 16 (36%) with Hodgkin’s lymphoma. Among 44 patients, 36 (82%) underwent chemotherapy during pregnancy, in 8 (18%), treatment was postponed until delivery. The median age of the patients at the time of the disease detection was 30 (range 20-39) years. In this retrospective single-center cohort study, we analyzed the development of 46 children born to 44 patients with detected lymphoma during gestation. Results. 43 (98%) of the 44 patients have been alive and are in remission of the disease with a median observation of 56 (range 2-186) months. 30 (68%) patients achieved complete remission after the first line of therapy. The remaining 14 (32%) patients required a second and subsequent line of treatment due to failure of the initial therapy. 6 (14%) cases of disease progression were registered during chemotherapy. Early relapses (1 year) — in 1 (2%) case. One patient died in the late postpartum period from septic complications after high-dose chemotherapy due to the progression of the disease. The median gestational age of newborns was 36 (range 26-40) weeks, 27 of 46 children (61%) were born prematurely. 22 newborns (49%) required follow-up in the intensive care unit. Congenital malformations of the cardiovascular system were detected in 2 babies (4%): 1 case (2%) of an open ductus arteriosus and 1 case (2%) of an interventricular septal defect. However, none of the identified pathological conditions required surgical intervention. At the time of the study, the median age of the children was 5.0 (range 0.3—15.3) years. The following LEN organs diseases were diagnosed later for 11 months among 46 children : adenoid hypertrophy — n=4 (9%), tonsillitis — n= 1 (2%), laryngitis — n=3 (7%), otitis media — n=3 (7%). One child (2%), whose mother did not receive chemotherapy during pregnancy, was diagnosed with cerebral palsy in the first year of life. Conclusion. Despite the diagnostic and therapeutic difficulties in verifying lymphoproliferative diseases during pregnancy, as well as the high frequency of premature birth, long-term catamnesis observations demonstrate favorable outcomes. The patients have long-term remissions, and the condition of their children is satisfactory in most cases.
- 26 August 2026
- Published by Media Sphere Publishing Group in Russian Bulletin of Obstetrician-Gynecologist
- Vol. 26 (4)
Lymphoproliferative diseases during pregnancy. Long-term outcomes for mother and child
Lymphoproliferative diseases are the third most common type of malignant neoplasms detected in pregnant patients. The high effectiveness of the therapy of such patients makes it relevant to study the long-term results of their treatment, as well as the health status of their children. Objective. To present the features of the course of pregnancy and its outcomes in patients with an identified lymphoproliferative disease during pregnancy, to evaluate the long-term effects of the treatment, as well as to analyze the physical development of children born to mothers with lymphoma, at birth and in the catamnesis. Materials and methods. From 2009 to 2025, 44 patients with a diagnosis of lymphoproliferative disease during pregnancy were treated at the Federal State Budgetary Institution “NMRC of Hematology” of the Ministry of Health of the Russian Federation. 28 (64%) pregnant women were diagnosed with non-Hodgkin’s lymphoma, 16 (36%) with Hodgkin’s lymphoma. Among 44 patients, 36 (82%) underwent chemotherapy during pregnancy, in 8 (18%), treatment was postponed until delivery. The median age of the patients at the time of the disease detection was 30 (range 20-39) years. In this retrospective single-center cohort study, we analyzed the development of 46 children born to 44 patients with detected lymphoma during gestation. Results. 43 (98%) of the 44 patients have been alive and are in remission of the disease with a median observation of 56 (range 2-186) months. 30 (68%) patients achieved complete remission after the first line of therapy. The remaining 14 (32%) patients required a second and subsequent line of treatment due to failure of the initial therapy. 6 (14%) cases of disease progression were registered during chemotherapy. Early relapses (1 year) — in 1 (2%) case. One patient died in the late postpartum period from septic complications after high-dose chemotherapy due to the progression of the disease. The median gestational age of newborns was 36 (range 26-40) weeks, 27 of 46 children (61%) were born prematurely. 22 newborns (49%) required follow-up in the intensive care unit. Congenital malformations of the cardiovascular system were detected in 2 babies (4%): 1 case (2%) of an open ductus arteriosus and 1 case (2%) of an interventricular septal defect. However, none of the identified pathological conditions required surgical intervention. At the time of the study, the median age of the children was 5.0 (range 0.3—15.3) years. The following LEN organs diseases were diagnosed later for 11 months among 46 children : adenoid hypertrophy — n=4 (9%), tonsillitis — n= 1 (2%), laryngitis — n=3 (7%), otitis media — n=3 (7%). One child (2%), whose mother did not receive chemotherapy during pregnancy, was diagnosed with cerebral palsy in the first year of life. Conclusion. Despite the diagnostic and therapeutic difficulties in verifying lymphoproliferative diseases during pregnancy, as well as the high frequency of premature birth, long-term catamnesis observations demonstrate favorable outcomes. The patients have long-term remissions, and the condition of their children is satisfactory in most cases.
- Open Access
- 17 July 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (2) , 227-237
Nivolumab and pregnancy in patients with classical Hodgkin lymphoma
Introduction . Classical Hodgkin lymphoma (cHL) is predominantly diagnosed in women of reproductive age. The expanding use of PD-1 inhibitors in the treatment of cHL increases the likelihood of pregnancy being detected during immunotherapy. However, only a limited number of such observations have been described in the literature, which complicates the choice of an optimal management strategy for these patients. Aim : to present two clinical case reports of patients with cHL: in the first, the beginning of pregnancy (4 weeks) occurred during nivolumab exposure; in the other patient, nivolumab was administered during the periconceptional period, 6 weeks before conception. Main Findings . In the first case, pregnancy was diagnosed at 6 weeks of gestation during maintenance therapy with nivolumab 40 mg every 2 weeks (cumulative dose 600 mg); the last dose was administered at 4 weeks of gestation, and treatment was discontinued after pregnancy was confirmed. Spontaneous delivery occurred at 38 weeks: a boy, birth weight 2910 g, length 49 cm, Apgar scores 8 and 9. In the second case, pregnancy was diagnosed at 3 weeks of gestation after completion of the Nivo-DHAP course with nivolumab at a dose of 240 mg. After pregnancy was confirmed, antitumor treatment was discontinued. Delivery at 38 weeks: cesarean section, a girl, birth weight 3000 g, length 52 cm, Apgar scores 8 and 9. The presented clinical case reports add to the limited clinical data on the course of pregnancy during the use of PD-1 inhibitors and highlight the need for multidisciplinary management and individualized decision-making, taking into account the potential risks to the mother and the fetus.
- 17 July 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (2) , 227-237
Open AccessNivolumab and pregnancy in patients with classical Hodgkin lymphoma
Introduction . Classical Hodgkin lymphoma (cHL) is predominantly diagnosed in women of reproductive age. The expanding use of PD-1 inhibitors in the treatment of cHL increases the likelihood of pregnancy being detected during immunotherapy. However, only a limited number of such observations have been described in the literature, which complicates the choice of an optimal management strategy for these patients. Aim : to present two clinical case reports of patients with cHL: in the first, the beginning of pregnancy (4 weeks) occurred during nivolumab exposure; in the other patient, nivolumab was administered during the periconceptional period, 6 weeks before conception. Main Findings . In the first case, pregnancy was diagnosed at 6 weeks of gestation during maintenance therapy with nivolumab 40 mg every 2 weeks (cumulative dose 600 mg); the last dose was administered at 4 weeks of gestation, and treatment was discontinued after pregnancy was confirmed. Spontaneous delivery occurred at 38 weeks: a boy, birth weight 2910 g, length 49 cm, Apgar scores 8 and 9. In the second case, pregnancy was diagnosed at 3 weeks of gestation after completion of the Nivo-DHAP course with nivolumab at a dose of 240 mg. After pregnancy was confirmed, antitumor treatment was discontinued. Delivery at 38 weeks: cesarean section, a girl, birth weight 3000 g, length 52 cm, Apgar scores 8 and 9. The presented clinical case reports add to the limited clinical data on the course of pregnancy during the use of PD-1 inhibitors and highlight the need for multidisciplinary management and individualized decision-making, taking into account the potential risks to the mother and the fetus.